Yahoo · Nov 12, 2026
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026Completed underwritten offering of Series A Common S

